Healthcare Industry News: hereditary angioedema
News Release - November 1, 2006
Pharming Shareholders Appoint Bruno Giannetti as Member of the Board of ManagementLeiden, The Netherlands, November 1, 2006 -- (HSMN NewsFeed) -- Biotech company Pharming Group NV ("Pharming") (Euronext: PHARM) (PHARM.AS) announced today that its shareholders have approved the appointment of Dr. Bruno Giannetti as member of the Board of Management of Pharming in the position of Chief Operations Officer effective December 1, 2006. The nomination of Dr. Giannetti was subject to shareholder approval at the Extraordinary Meeting of Shareholders held today in Leiden.
Dr. Giannetti (54) has more than 25 years experience in the pharmaceutical and biotech industry. He was Head of Clinical Research at Madaus, Germany and world-wide Vice-President Marketing and Medical Information at Immuno, Austria. He served as senior management consultant for pharmaceutical R&D projects at Coopers & Lybrand, Switzerland and UK and as Chief Operations Officer and subsequently President and CEO of Verigen AG, Germany. He is currently the CEO of AM-Pharma, The Netherlands.
Dr. Giannetti is the founder of CRM, a well established European Clinical Research Organization specialized in international pharmaceutical clinical research. He is a visiting lecturer at the University of Bonn and former President of the Biotech Group of the German Bio Pharmaceutical Industry Organization. He is also accredited as Qualified Person (relevant for the manufacturing of pharmaceutical products). He holds a PhD in chemistry and a MD PhD degree in medicine from the University of Bonn.
Background on Pharming Group NV
Pharming Group NV is developing innovative protein products for the treatment of genetic disorders, specialty products for surgical indications, intermediates for various applications and food products. Pharming has two products in late stage development - RhucinŽ (recombinant human C1 inhibitor) for hereditary angioedema (under review by EMEA) and human lactoferrin for use in functional foods (GRAS notification under review by US FDA). The advanced technologies of the Company include innovative platforms for the production of protein therapeutics, as well as technology and processes for the purification and formulation of these products. Recently, Pharming acquired DNage BV, giving it access to new technology platforms in the areas of cancer and ageing diseases. Additional information is available on the Pharming website, http://www.pharming.com.
This press release contains forward looking statements that involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company to be materially different from the results, performance or achievements expressed or implied by these forward looking statements. The press release also appears in Dutch. In the event of any inconsistency, the English version will prevail over the Dutch version.
Source: Pharming Group
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.